-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC).
In two Phase III trials (CheckMate 017 and CheckMate 057), Navu monoantigens further improved the overall survival rate (OS) of previously treated patients with advanced and non-scaly NSCLC, and were also more safe than dositan.
this paper reports on the five-year summary efficacy and safety results of these trials.
two trials in a total of 854 patients with advanced NSCLC, ECOG PS ≤1 and first-line platinum-based chemotherapy progressed/after, and were randomly divided into two groups, given narcisson (3 mg/kg, 1 time/2 weeks) or dossythal (75 mg/m, 1 time/3 weeks) until progress or unacceptable toxicity occurred.
the main endpoints of both trials are OS;
the OSCheckmate 017 and 057 trials in all patients had a minimum follow-up time of 64.2 and 64.5 months, respectively, and 50 and 9 patients who received Narcosmosis and dorsitasis were still alive, respectively.
OS rate was 13.4% and 2.6% respectively in the five-year period, and the five-year PFS rate was 8.0% and 0%, respectively.
survival rates were 82.0% and 93.0% for patients with no progression in 2 and 3 years of navuda resistance therapy for all patients, and 59.6% and 78.3% for 5 years without progression, respectively.
Between the 3rd and 5th years of follow-up, 31 treatment-related adverse events (TRAEs) were reported in patients treated with Navuda resistance, of which 7 had new adverse events, and 1 case (3.2%) had a level 3 and no level 4 TRAE.
five years of follow-up, the Navu monolith continued to show survival benefits compared to the Dosital, with the OS rate five times higher than that of the Sydass, and no new safety incidents.
this is the first five-year prognostic result of a phase III randomized clinical trial of programmed death protein 1 inhibitors for previously treated late NSCLC.
